0.25 mg of semaglutide Wegovy 0.25mg FlexTouch - 0.25mg | Novo Nordisk India Pvt Ltd Semaglo 0.25 mg (Semaglutide) Injection

Patients included in the trial had HbA1c 7 to 10% and were treated with either: diet and exercise alone or 1 to 3 oral antidiabetic drugs (metformin, sulfonylurea, glitazone or sodium-glucose co-transporter 2 inhibitor)

Because of the potential for TAMIFLU to inhibit replication of live attenuated influenza vaccine (LAIV) and possibly reduce efficacy of LAIV, avoid administration of LAIV within 2 weeks or 48 hours after TAMIFLU administration, unless medically necessary [see Drug Interactions (7.1)]

(Credit: Michael Siluk/UCG/Universal Images Group via Getty Images) The study period included the 2017 FDA approval of Ozempic for Type 2 diabetes and the 2021 approval of Wegovy for chronic weight management

43 , e47 (2015)

10.4093/dmj.2023.0277 8 CaiX.LiJ.WangM.SheM.TangY.LiJ.et al (2017)